Valeant to acquire Eyetech to boost ophthalmology presence
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals has agreed to acquire Eyetech, a privately-owned ophthalmic biotechnology company for an upfront payment and potential future milestones "that total significantly less than two times sales", it announced.